Literature DB >> 32502458

Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.

Craig Erker1, Benita Tamrazi2, Tina Y Poussaint3, Sabine Mueller4, Daddy Mata-Mbemba5, Enrico Franceschi6, Alba A Brandes6, Arvind Rao7, Kellie B Haworth8, Patrick Y Wen9, Stewart Goldman10, Gilbert Vezina11, Tobey J MacDonald12, Ira J Dunkel13, Paul S Morgan14, Tim Jaspan15, Michael D Prados16, Katherine E Warren17.   

Abstract

Response criteria for paediatric high-grade glioma vary historically and across different cooperative groups. The Response Assessment in Neuro-Oncology working group developed response criteria for adult high-grade glioma, but these were not created to meet the unique challenges in children with the disease. The Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group, consisting of an international panel of paediatric and adult neuro-oncologists, clinicians, radiologists, radiation oncologists, and neurosurgeons, was established to address issues and unique challenges in assessing response in children with CNS tumours. We established a subcommittee to develop response assessment criteria for paediatric high-grade glioma. Current practice and literature were reviewed to identify major challenges in assessing the response of paediatric high-grade gliomas to various treatments. For areas in which scientific investigation was scarce, consensus was reached through an iterative process. RAPNO response assessment recommendations include the use of MRI of the brain and the spine, assessment of clinical status, and the use of corticosteroids or antiangiogenics. Imaging standards for brain and spine are defined. Compared with the recommendations for the management of adult high-grade glioma, for paediatrics there is inclusion of diffusion-weighted imaging and a higher reliance on T2-weighted fluid-attenuated inversion recovery. Consensus recommendations and response definitions have been established and, similar to other RAPNO recommendations, prospective validation in clinical trials is warranted.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32502458     DOI: 10.1016/S1470-2045(20)30173-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   54.433


  21 in total

Review 1.  European Society for Paediatric Oncology (SIOPE) MRI guidelines for imaging patients with central nervous system tumours.

Authors:  Shivaram Avula; Andrew Peet; Giovanni Morana; Paul Morgan; Monika Warmuth-Metz; Tim Jaspan
Journal:  Childs Nerv Syst       Date:  2021-05-10       Impact factor: 1.475

Review 2.  Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.

Authors:  Benjamin M Ellingson; Matthew S Brown; Jerrold L Boxerman; Elizabeth R Gerstner; Timothy J Kaufmann; Patricia E Cole; Jeffrey A Bacha; David Leung; Amy Barone; Howard Colman; Martin J van den Bent; Patrick Y Wen; W K Alfred Yung; Timothy F Cloughesy; Jonathan G Goldin
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

Review 3.  Standard clinical approaches and emerging modalities for glioblastoma imaging.

Authors:  Joshua D Bernstock; Sam E Gary; Neil Klinger; Pablo A Valdes; Walid Ibn Essayed; Hannah E Olsen; Gustavo Chagoya; Galal Elsayed; Daisuke Yamashita; Patrick Schuss; Florian A Gessler; Pier Paolo Peruzzi; Asim K Bag; Gregory K Friedman
Journal:  Neurooncol Adv       Date:  2022-05-26

4.  Comparison of intraoperative and post-operative 3-T MRI performed at 24-72 h following brain tumour resection in children.

Authors:  Shivaram Avula; Tim Jaspan; Barry Pizer; Benedetta Pettorini; Deborah Garlick; Dawn Hennigan; Conor Mallucci
Journal:  Neuroradiology       Date:  2021-02-25       Impact factor: 2.804

Review 5.  MRI biomarkers in neuro-oncology.

Authors:  Marion Smits
Journal:  Nat Rev Neurol       Date:  2021-06-20       Impact factor: 42.937

6.  Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors.

Authors:  Lisbeth Marner; Michael Lundemann; Astrid Sehested; Karsten Nysom; Lise Borgwardt; René Mathiasen; Peder S Wehner; Otto M Henriksen; Carsten Thomsen; Jane Skjøth-Rasmussen; Helle Broholm; Olga Østrup; Julie L Forman; Liselotte Højgaard; Ian Law
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 12.300

7.  World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology.

Authors:  Erik P Sulman; David D Eisenstat
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

8.  Evaluation of the reporting quality of clinical practice guidelines on gliomas using the RIGHT checklist.

Authors:  Yongjie Yang; Yanfang Ma; Jingli Lu; Shuzhang Du; Jingmin Zhang; Haiyang Meng; Zhe Chen; Qiwen Zhang; Xiaojian Zhang; Wenyin Shi; Francesco Girolamo; Santiago Cepeda; Jian Kang
Journal:  Ann Transl Med       Date:  2021-06

Review 9.  Clinical Trial Considerations in Neuro-oncology.

Authors:  Eudocia Q Lee
Journal:  Curr Treat Options Oncol       Date:  2021-07-02

10.  Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors.

Authors:  Jian Peng; Daniel D Kim; Jay B Patel; Xiaowei Zeng; Jiaer Huang; Ken Chang; Xinping Xun; Chen Zhang; John Sollee; Jing Wu; Deepa J Dalal; Xue Feng; Hao Zhou; Chengzhang Zhu; Beiji Zou; Ke Jin; Patrick Y Wen; Jerrold L Boxerman; Katherine E Warren; Tina Y Poussaint; Lisa J States; Jayashree Kalpathy-Cramer; Li Yang; Raymond Y Huang; Harrison X Bai
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.